Small Civil Dulera® Pricing Investigation Disclosed In Latest Form 10-Q

Rather late last evening, Kenilworth filed its Q3 SEC Form 10-Q -- and at page 22 we find a new government investigation. There is no indication as to when the US Attorney from the Eastern District of Pennsylvania came knocking with this CID, but I'll bet a dollar that it wasn't long after Martin Shkreli's antics became public fodder. I say this because it looks to be very recent -- and Lilly received one as well.

Regular readers will recall that Dulera^® was a legacy Schering-Plough product, FDA approved in 2010. In late 2010, once it controlled Schering-Plough's legacy products -- Merck withdrew its application in the EU for approval of an aersolized fixed dose combo version, for a host of reasons. So it goes:

. . . .The Company has received a civil investigative demand from the U.S. Attorney’s Office, Eastern District of Pennsylvania which requests information relating to the Company’s contracting and pricing of Dulera Inhalation Aerosol with certain pharmacy benefit managers and Medicare Part D plans. The Company is cooperating with the investigation. . . .

Morning, one and all! Onward!